business
Anti-cancer Immunotherapy
Anti-cancer immunotherapy is a novel potential treatment that activates
the immune cells in our body to kill the cancer cells.
Comparison with other Immunotherapies
NK cells are the only immune cells that detect abnormal cells such as cancer cells and remove them immediately without any specific antigens. In accordance to this principle, NK cell based anti-cancer immunotherapy is known to be much safer than other immunotherapies.
| Item | NK Cell Therapy | Dendritic Cell (DC) Therapy | CAR-T Cell Therapy |
|---|---|---|---|
| Cell type | NK Cells | Dendritic Cells | T-cells |
| Target Antigens | Non-specific | Specific | Specific |
| Presence of Antigens | None | Natural | Artificial |
| Cancer-killing Cells | Direct killing | Induces T-cell activation | Direct killing |
| Immune response | Direct | Indirect | Direct |
| Safety | High | High | Low (Able to cause cytokine syndrome.) |
Advantages of the novel potential immunotherapy SuperNK
Safety
- Pre-clinical study confirms safety for clinical trials
- Clinical trial Phase 1/2a for Non-small cell lung cancer : Approved by the Korean FDA on Dec 14, 2018.
- Clinical trial Phase 1 for Malignant Neoplasm: Approved by the US FDA on Mar 1, 2019.
- Clinical trial Phase 1 for Plaque Psoriasis: Approved by the Mexico FDA on Jun 2019.
- Obtained the Advanced Regenerative Treatment Technology Permit from the Japanese Ministry of Health, Labor, and Welfare’s Regenerative Medicine Committee.
Excellent Anti-cancer Efficacy
Pre-clinical study confirms that SuperNK delays cancer cell growth and inhibits metastasis.
-
Delay of Cancer cell growth
-
Prevention of liver metastases in breast cancer
Super NK injection (n=10) - Large numbers of metastatic spots were observed in the liver
Super NK injection (n=12) - Almost no metastatic spots were observed in the liver.